[Chimeric antigen receptor T-cell therapy for multiple myeloma]

CD19 chimeric antigen receptor (CAR) T cell therapy is effective in B cell leukemia and lymphoma. Many researchers are attempting to develop CAR T cells for different types of cancer. B cell maturation antigen (BCMA) is shown to be a promising target for multiple myeloma (MM). However, the treatment for MM remains challenging, and many researchers are trying to identify better target molecules for MM treatment. We have reported that activated integrin β7 is an excellent target for CAR T cells against MM and are currently performing a clinical trial.